Safety Study of HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis

The patients enrolled in the trial will be successively allocated into three cohorts for HYNR-CS-Allo inj., 0.25 X 10\^6 cells/kg, 0.5 X 10\^6 cells/kg, 1 X 10\^6 cells/kg, according to the 3+3, up and down protocol design. The first treatment cohort will be 0.5 X 10\^6 cells/kg dose cohort.